Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Loyola University Of Chicago is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed among 4 distinct examiners, meaning each examiner is responsible for 1 matter. This spread indicates that the university's current prosecution workload is not concentrated under any individual examiner, which may facilitate parallel processing of its applications.
The portfolio involves 2 distinct art units, suggesting that the 4 pending office actions are categorized into 2 technical groups. BRETZ, COREY LANE is the busiest examiner for the portfolio, with 1 pending office action. This figure of 1 pending office action is the maximum assigned to any of the 4 distinct examiners currently reviewing the university's applications. With the pending workload split between 2 distinct art units, the university maintains a presence across its assigned technical classifications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
| CHUANG, SU-TING | 1 | 51.3% | +39.4% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| ALAM, DANYAL HASSAN | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18703672 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | BRETZ, COREY LANE | — |
| 18573753 | Systems and Methods for Processing Data Using Interference and Analytics Engines | CHUANG, SU-TING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546525 | ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF | HAVLIN, ROBERT H | 27d |
| 18573753 | Systems and Methods for Processing Data Using Interference and Analytics Engines | CHUANG, SU-TING | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18703672 | BAG3 METHODS AND USES FOR TREATMENT OF INFLAMMATION | BRETZ, COREY LANE | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18573753 | Systems and Methods for Processing Data Using Interference and Analytics Engines | CHUANG, SU-TING | — | §101§103§112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18546525 | ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF | HAVLIN, ROBERT H | 1626 | §103 | Final Rejection | 27d | Pending | Aug 15, 2023 |
| 18341330 | CORONAVIRUSES, VACCINES COMPRISING THE SAME, AND METHODS FOR PREVENTING DISEASE | ALAM, DANYAL HASSAN | 1672 | §102§112DP | Non-Final OA | — | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial